Advanced search
Publication Cover
Cancer Investigation Volume 19, 2001 - Issue 4
Submit an article Journal homepage
72
Views
44
CrossRef citations to date
0
Altmetric
Original

Gemcitabine in the Second-Line Therapy of Patients with Carcinoma of Unknown Primary Site: A Phase II Trial of the Minnie Pearl Cancer Research Network

John D. Hainsworth Sarah Cannon—Minnie Pearl Cancer Center, Centennial Medical Center, 250 25th Avenue, North, Suite 412, Nashville, Tennessee, 37203, U.S.A.; Sarah Cannon—Minnie Pearl Cancer Center, Centennial Medical Center, 250 25th Avenue, North, Suite 412, Nashville, Tennessee, 37203, U.S.A.
, M.D.,
Howard A. Burris III Sarah Cannon—Minnie Pearl Cancer Center, Centennial Medical Center, 250 25th Avenue, North, Suite 412, Nashville, Tennessee, 37203, U.S.A.
, M.D.,
Sharon W. Calvert Sarah Cannon—Minnie Pearl Cancer Center, Centennial Medical Center, 250 25th Avenue, North, Suite 412, Nashville, Tennessee, 37203, U.S.A.
, B.A.,
Noel T. Willcutt Sarah Cannon—Minnie Pearl Cancer Center, Centennial Medical Center, 250 25th Avenue, North, Suite 412, Nashville, Tennessee, 37203, U.S.A.
, R.N.,
Daniel C. Scullin Jr
, M.D.,
Jane Bramham
, M.D. &
F. Anthony Greco Sarah Cannon—Minnie Pearl Cancer Center, Centennial Medical Center, 250 25th Avenue, North, Suite 412, Nashville, Tennessee, 37203, U.S.A.
, M.D. show all
Pages 335-339 | Published online: 30 Apr 2001

REFERENCES

  • Schildt R. A., Kennedy P. S., Chen T. T., Athens J. W., O'Bryan R. M., Balcerzak S. P. Management of Patients with Metastatic Adenocarcinoma of UnknownOrigin: A Southwest Oncology Group Study. Cancer Treat. Rep. 1983; 67: 77–81
  • Johnson R. O., Castro R., Ansfield F. J. Response of Primary Unknown Cancers to Treatment with 5-Fluorouracil. Cancer Chemother. Rep. 1964; 38: 63–70
  • Moertel C. G., Reitemeier R. I., Shutt A. I., Hahn R. G. Treatment of the Patient with Adenocarcinoma of Unknown Origin. Cancer 1972; 36: 1469–1481
  • Goldberg R. M., Smith F. P., Ueno W., Ahlgren J. D., Schein P. S. Fluorouracil, Adriamycin, and Mitomycin in the Treatment ofAdenocarcinoma of Unknown Primary. J. Clin. Oncol. 1986; 4: 395–402
  • Raber M. N., Faintuch J., Abbruzzese J. L., Sumrall C., Frost P. Conitinuous Infusion 5-Fluorouracil, Etoposide, and cis-Diamminedichloroplatinumin Patients with Metastatic Carcinoma of Unknown Primary Origin. Ann. Oncol. 1991; 2: 519–521
  • Woods R. L., Fox R. M., Tattersall M. H.N., Levi J. A., Brodie G. N. Metastatic Adenocarcinoma of Unknown Primary: A Randomized Studyof Two Combination-Chemotherapy Regimens. N. Engl. J. Med. 1980; 303: 87–89
  • Becouarn Y., Bruner R., Barbe-Gaston C. Fluorouracil, Doxorubicin, Cisplatin and Altretamine in theTreatment of Metastatic Carcinoma of Unknown Primary. Eur. J. Cancer Clin. Oncol. 1989; 25: 861–870
  • Eagan R. T., Thermean T. M., Rubin J., Long H. J., Schutt A. J. Lack of Value for Cisplatin Added to Mitomycin-Doxorubicin CombinationChemotherapy for Carcinoma of Unknown Primary Site. Am. J. Clin. Oncol. 1987; 10: 82–90
  • Hess K. R., Abbruzzese M. C., Lenzi R., Abbruzzese J. L. Classification and Regression Tree Analysis of 1,000 ConsecutivePatients with Unknown Primary Carcinoma. Clin. Cancer Res. 1999; 5: 3403–3410
  • Hainsworth J. D., Erland J. B., Kalman L. A., Schreeder M. T., Greco F. A. Carcinoma of Unknown Primary Site: Treatment with One-Hour Paclitaxel,Carboplatin, and Extended Schedule Etoposide. J. Clin. Oncol. 1997; 15: 2385–2394
  • Abratt R. P., Bezwoda W. R., Falkson G., Goedhals L., Hacking D., Rugg T. A. Efficacy and Safety Profile of Gemcitabine in Non-Small CellLung Cancer: A Phase II Study. J. Clin. Oncol. 1994; 12: 1535–1540
  • Burris H. A., III, Moore M. S., Anderson J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P., Nelson R., Dorr F. A., Stephens C. D., Von Hoff D. D. Improvements in Survival and Clinical Benefit with Gemcitabineas First-Line Therapy for Patients with Advanced Pancreas Cancer: A RandomizedTrial. J. Clin. Oncol. 1997; 15: 2403–2413
  • Carmichael J., Possinger K., Phillip P., Beykirch M., Kerr H., Walling J., Harris A. L. Advanced Breast Cancer: A Phase II Trial with Gemcitabine. J. Clin. Oncol. 1995; 13: 2731–2736
  • Lund B., Hansen O. P., Theilade K., Hansen M., Neijt J. P. Phase II Study of Gemcitabine (2, 2-Difluorodeoxycytidine) inPreviously Treated Ovarian Cancer. J. Natl. Cancer Inst. 1994; 86: 1530–1533
  • Moore M. J., Tannock I. F., Ernst D. S., Huan S., Murray N. Gemcitabine: A Promising New Agent in the Treatment of AdvancedUrothelial Cancer. J. Clin. Oncol. 1997; 15: 3441–3445
  • Gallardo J., Fodor M., Gamargo C., Orlandi L. Efficacy of Gemcitabine in the Treatment of Patients with GallbladderCarcinoma. Cancer 1998; 83: 2419–2421

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.